Cervical Cancer

Measurability of Quality Performance Indicators
Version 2.2

To be read in conjunction with:

- **Cervical Cancer QPIs Final Publication v2.0**
- **Cervical QPI Dataset (latest published version)**

Measurability of Quality Performance Indicators for Cervical Cancer

Document control:

This Version

Title	Cervical Cancer Measurability of QPIs	**Version/Issue Number**	2.2
Effective From	October 2015	**Author**	Charlotte Anthony, ISD
Document Type	Guidance	**Document status**	Final – For Publication
Document Purpose	Final – For Publication		
Summary of changes			

Revision History

Version	Date	Status	Summary of Changes	QPI (s)
0.1	Feb 2014	Draft	First draft	All
0.2	Mar 2014	Draft	Changes following comments from KC	All
0.3	May 2014	Draft	Changes following public engagement	All
0.4	June 2014	Draft	Further changes following public engagement	All
0.5	Sept 2014	Draft	Changes following board review	All
2.0	June 2015	Final	Changes agreed at 9mth Review	1, 2, 3, 6,7
2.1	April 2016	Final	Amended outwith Review	1
2.2	Sept 2016	Final	Changes agreed at Baseline Review	1, 2, 3, 5, 7

Updates from Previous Version

QPI	Summary of changes (excluding formatting changes) (September 2016)
1	QPI title – removed 'first' inserted 'definitive'; Description removed 'first' inserted 'definitive'; Numerator - removed 'first' inserted 'definitive', changed 'Date of First Treatment' to 'Date of Definitive Treatment' – 'DEFTREATDATE', inserted 'OR Date of Definitive Treatment is coded as Not Applicable – OR [DEFTREATDATE = 10/10/1010]; Denominator – inserted the following exclusion 'patients with histopathological FIGO stage IVB disease and patients who refuse MRI investigation', inserted Final FIGO stage – 'OR IVB' and 'or Patient refused investigation – OR 95'; NR for Numerator amended FIRSTTREATDATE to DEFTREATDATE.
2	Denominator – inserted 'and Date of Surgery coded as Not Applicable – AND [SURGDATE = 10/10/1010]'; NR for Denominator inserted 'OR [SURGDATE = 09/09/0909]'
3	Denominator – inserted the following exclusion 'patients who died before first treatment', inserted 'and Type of First Cancer Treatment not coded as Patient died before treatment – AND [FIRSTTREATMODE <> 94]
5	Denominator – removed 'Excluding patients who undergo neo-adjuvant chemotherapy' inserted 'No Exclusions', removed 'and Type of Systemic Anti-Cancer Therapy (SACT 1) not coded as Neoadjuvant – AND [CHEMTYPE1 <> 01]'; NR for Exclusion – removed '[CHEMTYPE1 = 99] inserted 'NA'
7	NR Numerator – remove [CHEMTYPE1 = 99] **OR** [RADIOTYPE = 99] insert ([CHEMTYPE1 = '99' AND CHEMTYPE2 <> '5'] OR [CHEMTYPE2 = '99' AND CHEMTYPE1 <> '5'])

QPI	Summary of changes (excluding formatting changes) (April 2016)
1	Numerator changed from **(**[MRIDATE <> 10/10/1010] **AND** [MRIDATE < FIRSTTREATDATE]**)** to ([MRIDATE <> 10/10/1010] AND [MRIDATE ≤

	FIRSTTREATDATE])

QPI	**Summary of changes (excluding formatting changes) (July 2015)**
1	Remove abdomen from description and numerator
2	Den – add OR 06
3	Num - [MDTDATE <> 10/10/1010] AND ([MDTDATE ≤ DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010])
6	NR numerator - remove [RADIOTYPE = 99] **OR**
7	Num - add OR CHEMTYPE2 =05

QPI 1 – Radiological Staging

QPI Title:	Patients with cervical cancer should have their stage of disease assessed by magnetic resonance imaging (MRI) prior to definitive treatment.
Description:	Proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.
Numerator	Number of patients with cervical cancer having MRI of the pelvis carried out prior to definitive treatment. Date of MRI Scan Completed (Pre-treatment) not coded as not applicable and coded less than or equal to Date of Definitive Treatment OR Date of Definitive Treatment is coded as Not Applicable. ([MRIDATE <> 10/10/1010] AND [MRIDATE < DEFTREATDATE]) OR [DEFTREATDATE = 10/10/1010]
Denominator	All patients with cervical cancer. (*Excluding patients with histopathological FIGO[a] stage IA1 disease, patients treated by LLETZ[b] only, patients unable to undergo MRI due to contraindications, patients with histopathological FIGO stage IVB disease and patients who refuse MRI investigation*). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Final FIGO Stage {Cervical Cancer} not coded as IA1 or IVB; and Surgery Performed not coded as LEEP/LLETZ (LEEP, LLETZ OR CONE); and MRI Scan {Pre-Treatment} not coded as Contraindication to MRI or Patient refused investigation. ([FIGO <> IA1 or IVB] **AND** [SURG <>05 OR 06]) **AND** [MRI <> 98 or 95]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MRIDATE = 09/09/0909] **OR** [DEFTREATDATE = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [FIGO = 99] **OR** [SURG = 99] **OR** [MRI = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard

[a] FIGO – International Federation of Gynecology and Obstetrics
[b] Large Loop Excision of the Transformation Zone

QPI 2 – Positron Emission Tomography/Computed Tomography (PET/CT)

QPI Title:	Patients with cervical cancer, for whom primary definitive surgery is not appropriate, should undergo positron emission tomography - computed tomography imaging (PET/CT).
Description:	Proportion of patients with cervical cancer, for whom primary definitive treatment is radical radiotherapy, who have PET/CT imaging.
Numerator	Number of cervical cancer patients undergoing primary radical radiotherapy who have PET/CT imaging prior to starting treatment. Date of PET CT Scan {Cervical Cancer} (Pre-treatment) not coded as not applicable and coded as before Date Treatment Started (Radiotherapy) [PETSCAN <> 10/10/1010] **AND** [PETSCAN < RSTARTDATE]
Denominator	All patients with cervical cancer undergoing primary radical radiotherapy. *(No exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Radiotherapy Course Type coded as Radical OR Chemoradiotherapy; and Date of Surgery coded as Not Applicable. ([RADIOTYPE = 02 OR 06]) AND [SURGDATE = 10/10/1010]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [PETSCAN = 09/09/0909] **OR** [RSTARTDATE = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [RADIOTYPE = 99] OR [SURGDATE = 09/09/0909]

QPI 3 – Multidisciplinary Team Meeting (MDT)

QPI Title:	Patients with cervical cancer should be discussed by a multidisciplinary team (MDT) prior to definitive treatment.
Description:	Proportion of patients with cervical cancer who are discussed at a MDT meeting before definitive treatment.
Numerator	Number of patients with cervical cancer discussed at the MDT before definitive treatment. Date discussed by Care Team (MDT) not coded as Not applicable and Date discussed by Care Team (MDT) before or equal to Date of Definitive Treatment {Cervical Cancer} OR Date of Definitive Treatment {Cervical Cancer} coded as not applicable [MDTDATE <> 10/10/1010] AND ([MDTDATE ≤ DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010])
Denominator	All patients with cervical cancer. *(Excluding patients with histopathological FIGO[c] stage IA1 disease, patients treated by LLETZ[d] only and patients who died before first treatment).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final FIGO Stage {Cervical Cancer} not coded as IA1; and Surgery Performed not coded as LEEP/LLETZ(CONE) only; and Type of First Cancer Treatment not coded as Patient died before treatment. ([FIGO <> IA1] **AND** [SURG <>05 OR 06]) AND [FIRSTTREATMODE <>94]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MDTDATE = 09/09/0909] **OR** [DEFTREATDATE = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [FIGO = 99] OR [SURG = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard

[c] FIGO – International Federation of Gynecology and Obstetrics
[d] Large Loop Excision of the Transformation Zone

QPI 4 – Radical Hysterectomy

QPI Title:	Patients with stage IB1 cervical cancer should undergo radical hysterectomy.
Description:	Proportion of patients with stage IB1 cervical cancer (as defined by radiology and/or histopathology) who undergo radical hysterectomy.
Numerator	Number of patients with FIGO stage IB1 cervical cancer who undergo radical hysterectomy. Surgery Performed coded as Radical Hysterectomy. [SURG = 02]
Denominator	All patients with FIGO stage IB1 cervical cancer. *(Excluding patients who decline surgery, patients who undergo fertility conserving surgery and patients having neo adjuvant chemotherapy, patients enrolled into surgical trials).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final FIGO Stage {Cervical Cancer} coded as IB1, and Surgery Performed not coded as Trachelectomy, Radical Trachelectomy or Patient Refused Treatment; and Type of Systemic Anti-Cancer Therapy (SACT) 1 not coded as neo adjuvant; and Patient entered into Clinical Trial not coded as Yes – Surgical Trial. [FIGO = IB1] **AND** [SURG <> 03 OR 04 OR 95] **AND** [CHEMTYPE1 <> 01] **AND** [TRIAL <> 01A]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [SURG = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [SURG = 99] **OR** [CHEMTYPE1 = 99] **OR** [TRIAL = 99]
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [FIGO = 99]

QPI 5 – Surgical Margins

QPI Title:	Patients with surgically treated cervical cancer should have clear resection margins.
Description:	Proportion of patients with cervical cancer who have surgical margins clear of tumour following hysterectomy.
Numerator	Number of patients with cervical cancer who undergo surgery where surgical margins are clear of tumour. Margin Status {Cervical Cancer} coded as Clear [MARGIN = 01]
Denominator	All patients with cervical cancer who undergo surgery. *(No Exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Surgery Performed coded as Hysterectomy or Radical Hysterectomy or Trachelectomy or Radical Trachelectomy. ([SURG = 01 OR 02 OR 03 OR 04]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MARGIN = 99]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [SURG = 99]

QPI 6 – 56 Day Treatment Time for Radical Radiotherapy

QPI Title:	Treatment time for patients with cervical cancer undergoing radical radiotherapy should be no more than 56 days.
Description:	Proportion of patients with cervical cancer undergoing radical radiotherapy whose overall treatment time, from the start to the end of treatment, is not more than 56 days.
Numerator	Number of patients with cervical cancer undergoing radical radiotherapy (external beam or brachytherapy) whose overall treatment time, from start to end of treatment, is not more than 56 days. Date Treatment Completed (Radiotherapy) minus Date Treatment Started (Radiotherapy) coded as less than or equal to 56 days. ([RCOMPDATE – RSTARTDATE <= 56])
Denominator	All patients with cervical cancer undergoing radical radiotherapy – (external beam or brachytherapy) *(No exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Radiotherapy Course Type coded as Radical or Chemoradiotherapy. [RADIOTYPE = 02 OR 06]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [RSTARTDATE = 09/09/0909] **OR** [RCOMPDATE = 09/09/0909]
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [RADIOTYPE = 99]

QPI 7 – Chemoradiation

QPI Title:	Patients with cervical cancer undergoing radical radiotherapy should receive concurrent platinum-based chemotherapy.
Description:	Proportion of patients with cervical cancer undergoing radical radiotherapy who receive concurrent chemotherapy
Numerator	Number of patients with cervical cancer undergoing radical radiotherapy who receive concurrent chemotherapy. Radiotherapy Course Type coded as Radical and Type of Systemic Anti-Cancer Therapy (SACT) 1-2 coded as Chemoradiotherapy. [CHEMTYPE1 OR CHEMTYPE2 = 05]
Denominator	All patients with cervical cancer who undergo radical radiotherapy. *(No exclusions).* Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Radiotherapy Course Type coded as Radical. [RADIOTYPE = 02 OR 06]
Not recorded for numerator	Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target ([CHEMTYPE1 = '99' AND CHEMTYPE2 <> '5'] OR [CHEMTYPE2 = '99' AND CHEMTYPE1 <> '5'])
Not recorded for exclusion	Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A
Not recorded for denominator	Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [RADIOTYPE = 99]